Role of Personalized Medicine: Now and the Future Academic Article uri icon

abstract

  • The International Association for the Study of Lung Cancer recently published a proposal for a new staging classification of lung cancer (1). Data on which this staging system was based showed that the 5-year survival rates for stage IA, IB, IIA, and IIB lung cancer were 73%, 58%, 46%, and 36%, respectively. In other words, disease will recur in 27% of stage IA and 42% of stage IB patients (1). How do we identify those patients who are most likely to suffer disease recurrence and how do we choose the most effective therapy? While adjuvant therapy is established for stage II disease, there is no consensus regarding adjuvant therapy for stages IA and IB despite the relatively low survival rates. Thus, there is a need for biomarker selection of patients in these stages in order to better select those who would benefit from adjuvant therapy. Biomarkers in lung cancer can be applied for different …

publication date

  • October 25, 2010